ArticleFrontiers in oncology2026
Plasticizers and prostate cancer: unraveling the link through network toxicology and machine learning.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Plasticizers, as widespread environmental endocrine disruptors, are increasingly linked to an elevated risk of prostate cancer (PCa). However, the specific molecular mechanisms by which they drive PCa initiation and progression remain incompletely elucidated. Addressing this knowledge gap is crucial for assessing environmental health risks and identifying potential intervention targets. Methods: This study employed a multi-level integrated research strategy. First, the toxicological profiles of target plasticizers were predicted using ADMETlab and ProTox platforms. Second, plasticizer-related targets were identified by integrating multiple databases and then cross-referenced with differentially expressed genes in PCa from TCGA and GEO cohorts to obtain shared targets. Subsequently, a protein-protein interaction (PPI) network was constructed and analyzed topologically. GO and KEGG enrichment analyses were performed to explore underlying biological processes and pathways. A total of 98 combination prediction models based on 10 machine learning algorithms were developed and evaluated to identify core prognostic genes. Furthermore, single-cell and spatial transcriptomics data were utilized to examine the expression localization of core genes within the tumor microenvironment. Molecular docking simulations were conducted to validate the binding affinity between plasticizers and core target proteins. Finally, Results: Toxicity predictions confirmed the carcinogenic potential of DEP, DMP, and DOP. A total of 183 bridging genes connecting plasticizers and PCa were identified. Enrichment analysis revealed their significant involvement in key pathways including inflammatory response, cell cycle, p53 signaling, and chemical carcinogenesis. PPI network analysis preliminarily screened hub genes such as ALB and MMP9. Through systematic machine learning modeling and prognostic analysis, the core targets were further narrowed down to PLK1, ALB, and CCNA2. Among these, high expression of PLK1 was significantly associated with shorter disease-free survival in multiple independent cohorts. Molecular docking results indicated that all three plasticizers could bind stably to the PLK1 protein with high affinity (binding free energy < -5.0 kcal/mol). Single-cell and spatial transcriptomic analyses showed high expression of PLK1 in tumor epithelial cells. Conclusion: This study integrates computational toxicology, bioinformatics, machine learning, and experimental validation to reveal that common plasticizer exposure may promote PCa progression through dysregulation of cell cycle and inflammatory pathways, with PLK1 identified as a central molecular target. These findings establish a multi-omics evidence chain supporting the carcinogenic potential of environmental endocrine disruptors and provide a scientific basis for considering PLK1 as both a biomarker for risk assessment and a therapeutic target in plasticizer-associated PCa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.